Tiffany Lee, PharmD, BCIDP

Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.

Investigators examined the efficacy and safety of carbapenems vs select novel antibiotics for treatment of cUTI.

Although dalbavancin is currently approved by the US Food and Drug Administration for the treatment of skin and soft tissue infections, its distinctive pharmacokinetic profile has piqued curiosity regarding its place in therapy for infections requiring long durations of antibiotics, such as osteomyelitis.

Alternative agents are often broader spectrum than ß-lactams, subjecting patients to collateral damage and subsequent selection for resistant organisms and Clostridium difficile.

Many patients with pneumonia are empirically treated with anti-MRSA therapy, leaving antimicrobial stewardship programs faced with the challenge of identifying patients who truly warrant continuation of this therapy.